902494-31-9

Basic information

• Product Name: TERT-BUTYL [1-(TRIFLUOROMETHYL)CYCLOPROPYL]CARBAMATE
• Synonyms: TERT-BUTYL [1-(TRIFLUOROMETHYL)CYCLOPROPYL]CARBAMATE
• CAS NO: 902494-31-9
• Molecular Formula: C9H14F3NO2
• Molecular Weight: 225.2081696
• Mol File: 902494-31-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 228.006°C at 760 mmHg
• Flash Point: 91.695°C
• Appearance: /
• Density: 1.206g/cm³
• Vapor Pressure: 0.075mmHg at 25°C
• Refractive Index: 1.423
• CAS DataBase Reference: TERT-BUTYL [1-(TRIFLUOROMETHYL)CYCLOPROPYL]CARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL [1-(TRIFLUOROMETHYL)CYCLOPROPYL]CARBAMATE(902494-31-9)
• EPA Substance Registry System: TERT-BUTYL [1-(TRIFLUOROMETHYL)CYCLOPROPYL]CARBAMATE(902494-31-9)

Safety Data

• Hazardous Substances Data: 902494-31-9(Hazardous Substances Data)

Usage

General Description

Tert-butyl [1-(trifluoromethyl)cyclopropyl]carbamate is a chemical compound that consists of a tert-butyl group attached to a carbamate functional group, which in turn is connected to a cyclopropyl ring with a trifluoromethyl substituent. It is commonly used as a reagent in organic synthesis due to its stability and ability to protect other functional groups during reactions. The trifluoromethyl group provides increased lipophilicity and electron withdrawing properties, making this compound useful in medicinal chemistry for the development of new drugs. Additionally, the cyclopropyl ring imparts unique geometric constraints that can influence the reactivity and selectivity of reactions involving this compound.

InChI:InChI=1/C9H14F3NO2/c1-7(2,3)15-6(14)13-8(4-5-8)9(10,11)12/h4-5H2,1-3H3,(H,13,14)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 277756-46-4 1-(trifluoromethyl)cyclopropanecarboxylic acid 
• 75-65-0 tert-butyl alcohol 

Relevant articles and documents

THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain

The discovery of a novel, selective and fully efficacious CB2 agonist with satisfactory pharmacokinetic and pharmaceutical properties is described. Compound 6 was efficacious in a rat model of osteoarthritis pain following oral administration and, in contrast to morphine, maintained its analgesic effect throughout a 5-day subchronic treatment paradigm. These data were consistent with our hypothesis that full agonist efficacy is required for efficient internalization and recycling of the CB2 receptor to avoid tachyphylaxis. Based on its overall favorable preclinical profile, 6 (APD371) was selected for further development for the treatment of pain.

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.